注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Anavex Life Sciences Corp是一家临床阶段的生物制药公司。该公司致力于开发用于治疗神经退行性疾病和神经发育疾病的差异化疗法。其先导化合物ANAVEX2-73正在开发用于治疗阿尔茨海默病、帕金森病和其他中枢神经系统疾病,包括罕见疾病,如雷特综合征是一种由X-连锁基因、甲基-CpG结合蛋白2(MECP2)引起的罕见的严重神经单基因疾病。其候选产品还包括ANAVEX 3-71、ANAVEX 1-41、ANAVEX 1066和ANAVEX 1037。ANAVEX 3-71是一种治疗认知障碍的中枢神经系统(CNS)可穿透的潜在疾病改善疗法。ANAVEX 1-41是一种sigma-1激动剂。ANAVEX 1066是一种混合sigma-1/sigma-2配体,设计用于治疗潜在治疗神经性和内脏疼痛。ANAVEX 1037专为治疗前列腺癌和胰腺癌而设计。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Timo Grimmer | - | 2022 | Member of Scientific Advisory Board |
Marwan Noel Sabbagh | 57 | 2023 | Member of Scientific Advisory Board |
John Harrison | - | 2013 | Member of the Scientific Advisory Board |
Claus van der Velden | 50 | 2018 | Lead Independent Director |
Peter Donhauser | 57 | 2017 | Independent Director |
Jiong Ma | 59 | 2021 | Independent Chairman |
Tangui Nicolas Maurice | - | - | Member of the Scientific Advisory Board |
Norman Relkin | - | 2014 | Member of the Scientific Advisory Board |
Athanasios Skarpelos | 56 | 2013 | Independent Director |
Andrew J. Cole | - | 2017 | Member of Scientific Advisory Board |
Christopher U. Missling | 57 | 2013 | President, CEO, Secretary & Director |
Steffen Thomas | 58 | 2015 | Independent Director |
Daniel Weintraub | - | 2016 | Member of the Scientific Advisory Board |
Ottavio Arancio | - | 2013 | Member of the Scientific Advisory Board |
Corinne Lasmézas | - | 2015 | Member of the Scientific Advisory Board |
Paul S. Aisen | - | 2011 | Member of the Scientific Advisory Board |
Jacqueline A. French | - | 2015 | Member of the Scientific Advisory Board |
Dag Aarsland | - | 2018 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核